Patent ID: 11903951
Assignee: M ET P PHARMA AG
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 14:
15. A method for treating a condition comprising nasally administering the composition of claim 1 to a subject in need thereof, wherein:
(a) the condition is hypogonadism, female sexual dysfunction, female arousal disorder, anorgasmia, or hypoactive sexual desire disorder, and the active agent is testosterone;
(b) the condition is a brain injury, and the active agent is progesterone;
(c) the condition is schizophrenia, and the active agent is aripiprazol, auetiapin, or paliperidon;
(d) the condition is anxiety, and the active agent is duloxetine or dopamine;
(e) the condition is multiple sclerosis, and the active agent is testosterone, glatirameracetat, interferon beta-1a, interferon beta-1b, fingolimod, natalizumab, or dimethylfumarat;
(f) the condition is Alzheimer's disease, and the active agent is pregnenolone, memantine, rivastigmin, or donepezil;
(g) the condition is depression, and the active agent is desvenlafaxine, duloxetine, or dopamine;
(h) the condition is insomnia, and the active agent is progesterone, eszopiclone or eszopiclone;
(i) the condition is attention deficit hyperactive disorder, and the active agent is tomoxetin, guanfacine, methylphenidate, lisdexamfetamine, or dopamine;
(j) the condition is traumatic brain injury, and the active agent progesterone or recombinant tissue plasminogen activator (rt-PA);
(k) the condition is a brain tumor, and the active agent is methotrexate, raltitrexed, 5-fluorouracil, telomerase inhibitor, or monoclonal antibodies;
(l) the condition is epilepsy, and the active agent is midazolam, lacosamide, levetiracetam, lamotrigine, or valproic acid;
(m) the condition is pain, and the active agent is oxycodone, pregabalin, buprenorphine, hydrocodone, or fentanyl; or
(n) the condition is Parkinson's disease, and the active agent is safinamide, ropinirole, pramipexole, dopamine, L-DOPA, selegiline, cabergoline, or istradefylline.